Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

80.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Traders See Bumpy Road Ahead For Gilead Sciences
Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses. 
Via Benzinga
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic. 
Via Benzinga
Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions
Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture... 
Via Benzinga
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
 
Via Benzinga
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market... 
Via Benzinga
Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
 
Via Benzinga
Why These Analysts Are Bullish On Gilead's Q1 Earnings
 
Via Benzinga
What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy
 
Via Benzinga
There Are Some Serious Deals In The Market Right Now
Interested in buying high-quality dividend growth stocks on sale? Want to know my top five stocks for June 2022? Then you have to check out this video. 
Via Talk Markets
7 Great ETFs to Buy Now for Momentum in Q2
These seven ETFs to buy are among the best funds. YPS, BITQ, FMET, QQMG, DVY, XSD, and VHT can make excellent investments. 
Via InvestorPlace
Sunshine Biopharma States It Is Developing COVID Antiviral That Could Play Important Role In Treating Endemic COVID
Image provided by Pexels 
Via Benzinga
7 Oversold Stocks to Buy Right Now
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. 
Via InvestorPlace
June 2022 Stock Considerations
With the start of a new trading month, it is time, once again, to highlight some potential stock buys for June. 
Via Talk Markets
7 Safe Dividend Stocks With High Yields to Buy Now
Investors are seeking dividend stocks. Here are seven safe dividend stocks that offer a high yield to maximize their total return. 
Via InvestorPlace
Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?
 
Via Benzinga
Murder For Hire? What You Need To Know About Enochian Biosciences Co-Founder's Arrest
The co-founder of Enochian Biosciences Inc (NASDAQ: ENOB) was arrested Wednesday following a two-year investigation into a man who was kidnapped and found dead in January 2018. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
 
Via Benzinga
Recent Stock Purchase May 2022
I have been busy buying up some stock this month and was happy to put some fresh capital to work to try and recoup some of my lost dividend income courtesy of the numerous cuts bestowed upon my... 
Via Talk Markets
Gilead Stock Earns Rating Upgrade After Quick Turnaround
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Where Gilead Sciences Stands With Analysts
Over the past 3 months, 10 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Dirt-Cheap Stock Looks Attractive And Pays A Market-Smashing Yield
After all, if you got a health problem, you're going to do whatever is necessary to get treatment. Demand for these products is inelastic and growing. And that means a long runway for revenue, profit,... 
Via Talk Markets
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
Stocks Are Undervalued
The bear growled this past week as the S&P 500 Index skirted the (-20%) threshold. But Friday the markets bounced back, much to investors’ relief. The Index is still in a correction, although that may... 
Via Talk Markets
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped. 
Via Investor's Business Daily
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Roche isn't the only company working on an anti-TIGIT molecule. 
Via Investor's Business Daily
Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings
 
Via Benzinga
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet. 
Via Benzinga
Pfizer: The Treasure of Albert Bourla
Pfizer won the lottery with Covid-19, but how it invests that cash will determine how well the stock does in the longer-term. 
Via InvestorPlace
May 2022 Stock Considerations
Let’s take a look at my May stock considerations. 
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.